ADAR1 Capital Management »

Vistagen Therapeutics Ord shares owned by ADAR1 Capital Management

Quarter-by-quarter ownership of Vistagen Therapeutics Ord (VTGN) shares owned by ADAR1 Capital Management from 13F filings

Historical chart of ADAR1 Capital Management investment in Vistagen Therapeutics Ord

Tip: Access up to 7 years of quarterly data

All positions including Vistagen Therapeutics Ord held by ADAR1 Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Vistagen Therapeutics Ord by ADAR1 Capital Management

Quarter filed Position value Share count Share price at filing
2024-03-31 $475k 90k 5.28
2023-12-31 $1.3M 246k 5.14

More positions owned by ADAR1 Capital Management

Alnylam Pharmaceuticals (ALNY)
Ea Series Trust Alpha Arch 1-3 (BOXX)
Roivant Sciences SHS (ROIV)
Spdr S&p 500 Etf Tr Tr Unit Put Option (SPY)
Protagonist Therapeutics (PTGX)
Cytokinetics Com New (CYTK)
Keros Therapeutics (KROS)
Royalty Pharma Shs Class A (RPRX)
Bridgebio Pharma (BBIO)
Merrimack Pharmaceuticals In Com New
Ascendis Pharma A/s Sponsored Adr (ASND)
Arbutus Biopharma (ABUS)
Avrobio Ord (AVRO)
Beigene Sponsored Adr (BGNE)
Invesco Qqq Tr Unit Ser 1 Put Option (QQQ)

View all positions for ADAR1 Capital Management

Top funds holding Vistagen Therapeutics Ord

BVF
Stempoint Capital
Vanguard Group
Commodore Capital
Nantahala Capital Management
Sphera Funds Management
Dr. Jeffrey R. Jay, M.D.
BlackRock
BlackRock
Citadel Advisors
Armistice Capital
Geode Capital Management
Susquehanna International
Renaissance Technologies
Goldman Sachs Group

View all funds holding Vistagen Therapeutics Ord